Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 154Cyclophosphamide 116fludarabine phosphate 109fludarabine 68Mycophenolic Acid 62Whole-Body Irradiation 56ibrutinib 46Tacrolimus 46Peripheral Blood Stem Cell Transplantation 44Lenalidomide 43Cyclosporine 36Busulfan 35Bendamustine Hydrochloride 34Antilymphocyte Serum 31ofatumumab 30obinutuzumab 28Melphalan 28idelalisib 26Alemtuzumab 26Filgrastim 25Methotrexate 23venetoclax 22Chlorambucil 21Granulocyte Colony-Stimulating Factor 20acalabrutinib 19thymoglobulin 18Cyclosporins 16Sirolimus 15Etoposide 15Pentostatin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Lymphocytic, Chronic, B-Cell × Pyrimethamine × Clear all
NCT01066663 2023-02-22

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡